In this issue
Our latest symposium review summarises several Boehringer Ingelheim presentations and posters on the role of nerandomilast, an oral investigational phosphodiesterase 4B inhibitor, for the treatment of idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF).
Rate this content's potential impact on patient outcomes
Average rating / 5. Vote count:
No votes so far! Be the first to rate this content.
Latest articles
All articles



We’ve noticed you’re accessing
from North/South America.
from North/South America.